Evusheld reduces risk of symptomatic COVID-19 in high-risk p

Evusheld reduces risk of symptomatic COVID-19 in high-risk population

Phase III trial shows Evusheld (tixagevimab and cilgavimab) reduces the risk of developing symptomatic COVID-19 in vulnerable populations. 

Related Keywords

Colorado , United States , Myron Levin , Astrazeneca , University Of Colorado School Medicine , Provent Phase , Colorado School , Executive Vice President ,

© 2025 Vimarsana